Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
Feature|Videos|January 27, 2026
The Benefits of SaaS for Laboratory Informatics
Author(s)Leslie Wubbel, LabVantage
Key Takeaways
- Learn about trends in the LIMS space, including the growing biopharmaceutical market, AI, and cloud computing.
- Understand the value add for laboratories that purchase SaaS and the total cost of ownership.
LabVantage is advancing software as a service (SaaS) for the laboratory information management system (LIMS) market to provide laboratories with reduced costs and pre-validated solutions that facilitate scalability and faster speed-to-market for pharmaceuticals
Leslie Wubbel, SaaS Product Manager at LabVantage Solutions, explains how transitioning to a SaaS model for the LIMS market reduces the total cost of ownership by replacing expensive on-premises infrastructure with simple subscription fees. This platform facilitates faster innovation through rapid AI deployment, improved search capabilities, and pre-validated solutions specifically tailored for the pharmaceutical industry. By utilizing these tools, laboratories can scale operations globally, ensure regulatory compliance, and significantly accelerate the speed-to-market for therapies.
Related to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.